retatrutide clinical trial information Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Retatrutide Phase 3: TRIUMPH Program

Department of Neuroscience, Georgetown University Medical Center, Washington, DC 20007, USA

Benefits Timeline Week 1-2: Food noise reduction, quieting of cravings begins Month 1: 2-4 pound loss typical, nausea under 10% for microdosers Month 3: 5-8% total body weight loss sustained Microdosing can support natural satiety and mindful eating, making it easier to build sustainable healthy habits rather than relying solely on the medication

Nausea and vomiting occurred in 39.29%

Studies have shown that these medications can reduce the risk of heart attacks, strokes, kidney disease, obstructive sleep apnea and now possibly cancer